VERTEX PHARMACEUTICALS (EUROPE) LIMITED

Kexing Biopharm has entered a strategic partnership with IQVIA in August 2025 to accelerate global clinical development and regulatory approval of its innovative drugs and biosimilars, particularly targeting Europe and other regulated international markets.

Vertex Pharmaceuticals announced that its experimental non-opioid pain reliever VX-993 failed to significantly outperform placebo in a Phase 2 trial for acute pain treatment.

Frazier Healthcare Partners has successfully closed a $1.3 billion venture capital fund specifically targeting early-stage biotechnology companies and startup creation.

The Centers for Medicare & Medicaid Services unveiled a new outcomes-based payment model with 33 states to expand Medicaid access to gene therapies for sickle cell disease.

Renasant Bio secured $54.5 million in seed funding from investors including 5AM Ventures, Atlas Venture, OrbiMed and Qiming Venture Partners USA to develop treatments for autosomal dominant polycystic kidney disease (ADPKD).

Vertex presented longer-term data for CASGEVY at the 2025 European Hematology Association Congress, demonstrating sustained clinical benefits with follow-up extending over 5.5 years for sickle cell disease patients and over 6 years for transfusion-dependent beta thalassemia patients.

Vertex Pharmaceuticals and Ono Pharmaceutical have entered an exclusive collaboration and license agreement to develop and commercialize povetacicept, a dual BAFF/APRIL antagonist, in Japan and South Korea for serious B cell-mediated kidney diseases.

CRISPR Therapeutics reported initial top-line results from an early-stage study on CTX310, showing peak reductions of up to 82% in triglycerides and 81% in LDL cholesterol with a single dose.

Saudi Arabia inaugurated its first-ever national pavilion at BIO International Convention 2025 in Boston, showcasing its ambition to become a global biotechnology hub under Vision 2030.

Pharmacists are uniquely positioned to lead the implementation of advanced cell and gene therapies, serving as both clinical and operational experts in health systems managing these complex treatments.